A perspective on the regulation of the evaluation of new antithrombotic drugs.


We have entered a period of great possibility for improving clinical outcomes for patients with arterial thrombotic disorders using new antithrombotic agents. A variety of new therapies are now in clinical trials, while several others have just received regulatory approval for use in clinical practice. Because of the increasing complexity of the clinical… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.